Prime Bank PLC, in partnership with Bangladesh Insurance Academy (BIA), has recently conducted a three-day training course on ...
Entrada Therapeutics can plough on with the development of its Duchenne muscular dystrophy (DMD) therapy, ENTR-601-44, now ...
Following a more than two-year-long hold, Entrada Therapeutics can get its Duchenne muscular dystrophy candidate back on ...
The US Food and Drug Administration (FDA) has lifted the clinical hold on ENTR-601-44 and provided authorization to initiate ELEVATE-44-102, a Phase Ib multiple ascending dose (MAD) clinical study of ...
Jae Hyun Park, DMD, PhD, was selected to be the next editor-in-chief of the American Journal of Orthodontics and Dentofacial Orthopedics and AJO-DO Clinical Companion, effective June 1.
Mitchell: Officially, by the first birthday, or within six months of the first tooth’s coming in. The first appointment is ...
Avidity Biosciences specializes in RNA-based therapies using Antibody-oligonucleotide conjugates to deliver drugs directly to ...
If, during your brushing and flossing routine, you notice white spots on your tongue, it might be time to schedule a check-up ...
Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...
Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne ...
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transfo ...
Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with ...